Pfizer prevails over Teva Novopharm on Canadian Viagra patent

Pfizer has prevailed over Teva Novopharm in its Canadian patent infringement litigation involving a generic version of Viagra (sildenafil). A federal judge has declared that the company has "met its legal burden" in establishing the validity of patent No 2,163,446.

Pfizer has prevailed over Teva Novopharm in its Canadian patent infringement litigation involving a generic version of Viagra (sildenafil). A federal judge has declared that the company has "met its legal burden" in establishing the validity of patent No 2,163,446.

Judge Michael Kelen of the Federal Court of Canada, in a June 18th ruling, prohibited the Canadian minister of health...

More from Cardiovascular

More from Therapeutic Category

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By 

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.